High-dose therapy with autologous transplantation for Hodgkin's disease: The Bologna experience

Haematologica

Volumn 88, Issue 5, 2003, Pages 522-528

  Zinzani, Pier Luigi ^a,b   Tani, Monica ^a   Gabriele, Annalisa ^a   Gherlinzoni, Filippo ^a   De Vivo, Antonio ^a   Ricci, Paolo ^a   Bandini, Giuseppe ^a   Lemoli, Roberto Massimo ^a   Motta, Maria Rosa ^a   Rizzi, Simonetta ^a   Giudice, Valeria ^a   Zompatori, Maurizio ^a   Stefoni, Vittorio ^a   Alinari, Lapo ^a   Musuraca, Gerardo ^a   Bassi, Simona ^a   Conte, Roberto ^a   Pileri, Stefano ^a   Tura, Sante ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ABMT; Chemotherapy; Hodgkin's disease; Relapse free survival

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; PREDNIMUSTINE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPHIL; RETROSPECTIVE STUDY; SCHOOL CHILD; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; RECURRENCE; RETROSPECTIVE STUDIES; SPAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0038439525     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998;16:3810-21.
2. Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 2000;18:972-80.
3. Klimo P, Connors JM. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol 1988;25 Suppl 2:34-40.
4. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84.
5. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002;20:221-30.
6. Hoppe RT. Development of effective salvage treatment programs for Hodgkin's disease: an ongoing challenge. Blood 1991;77:2093-5.
7. Longo DL, Duffey PL, Young RC, Hubbard SM, lhde DC, Glatstein E, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992;10:210-8.
8. Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989;7:179-85.
9. Desch CE, Lasala MR, Smith TJ, Hillner BE. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol 1992; 10:200-9.
10. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993;81:1137-45.
11. Yahalom J, Gulati SC, Toia M, Maslak P, McCarron EG, O'Brien JP, et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993;11:1062-70.
12. Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994;83: 1193-9.
13. Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995;85: 1381-90.
14. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997;89:814-22.
15. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801-13.
16. Subirȧ M, Sureda A, Martino R, Garcia J, Altes A, Canals C, et al. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen. Haematologica 2000;85:167-72.
17. Fermè C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20:467-75.
18. Czyz J, Hellmann A, Dziadziuszko R, Hansz J, Gozdzik J, Holowiecki J, et al. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplant 2002;30:29-34.
19. Sureda A, Arranz R, lriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Mėdula Osea Spanish Cooperative Group. J Clin Oncol 2001; 5:1395-404.
20. Nachbaur D, Oberaigner W, Fritsch E, Nussbaumer W, Gastl G. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience. Eur J Haematol 2001; 66:43-9.
21. Dowling AJ, Prince HM, Wirth A, Wolf M, Januszewicz EH, Juneja S, et al. High-dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience. Intern Med J 2001;31:279-89.
22. Anselmo AP, Meloni G, Cavalieri E, Proia A, Enrici RM, Funaro D, et al. Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients. Ann Hematol 2000;79:79-82.
23. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bonemarrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341: 1051-4.
24. Pfreundschuh MG, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994;12:580-6.
25. Fernandez-Jimenez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernandez-Navarro F. Hodgkin's disease, recurrent disease, salvage therapy, mini-BEAM, bone marrow transplantation. Haematologica 1999;84:1007-11.
26. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. German Hodgkin's Lymphoma Study Group. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Lancet 2002;359:2065-71.
27. Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994;12:279-87.
28. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280-6.
29. Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993;11:704-11.
30. Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994;83:1193-9.
31. Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995;85: 1381-90.
32. Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996;2:76- 85.
33. Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002;87:816-21.
34. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working. Group. J Clin Oncol 1999;17:1244.
35. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. JAMA 1958;53:457-81.
36. Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1958; 22:719-23.
37. Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 1997; 33:848-53.
38. Specht L, Horwich A, Ashley S. Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease. Int J Radiat Oncol Biol Phys 1994;30:805-11.
39. Andrė M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stemcell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Sociėtė Francaise de Graffe de Moette. J Clin Oncol 1999;17:222-9.
40. Lazarus HM, Loberiza FR Jr, Zhang M J, Armitage JO, Batten KK, Bashey A, et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Tansplant 2001;27:387-96.
41. Andrė M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998;92:1933-40.
42. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stemcell transplantation for lymphoid malignancies. J Clin Oncol 1994;12:2527-34.
43. Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000;18:2615-9.
44. Zinzani PL, Bendandi M, Stefoni V, Albertini P, Gherlinzoni F, Tani M, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000;85: 926-9.
45. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506-14.
46. Bierman PJ, Lynch JC, Bociek RG, Whalen VL, Kessinger A, Vose JM, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002;13:1370-7.
47. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995;13:1080-8.
48. Diehl V, Sieber M, Ruffer U, Lathan B, Hasendever D, Pfreundschuh M, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997;8:143-8.